Business ❯ Pharmaceuticals ❯ Market Competition
Novo Nordisk GLP-1 Drugs Weight Loss Treatments
The purchase marks Pfizer’s pivot toward cardiometabolic drugs following setbacks in its oral GLP‑1 program.
